Curry S, Lieb W R, Franks N P
Biophysics Section, Blackett Laboratory, Imperial College of Science, Technology, and Medicine, London, U.K.
Biochemistry. 1990 May 15;29(19):4641-52. doi: 10.1021/bi00471a020.
The effects of a diverse range of 36 general anesthetics and anesthetic-like compounds on a highly purified preparation of the bacterial luciferase enzyme from Vibrio harveyi have been investigated. Under conditions where the flavin site was saturated, almost all of the anesthetics inhibited the peak enzyme activity and slowed the rate of decay. However, a small number of the more polar agents only inhibited at high concentrations, while stimulating activity at lower concentrations. The inhibition was found to be competitive in nature, with the anesthetics acting by competing for the binding of the aldehyde substrate n-decanal. The anesthetic binding site on the enzyme could accommodate only a single molecule of a large anesthetic but more than one molecule of a small anesthetic, consistent with the site having circumscribed dimensions. The homologous series of n-alcohols and n-alkanes exhibited cutoffs in inhibitory potency, but these cutoffs occurred at very different chain lengths (about C10 for the n-alkanes and C15 for the n-alcohols), mimicking similar cutoffs observed for general anesthetic potencies in animals. Binding constants determined from peak height measurements showed that the inhibitor binding site was predominantly hydrophobic (with a mean delta delta G CH2 of -5.0 kJ/mol), but fluctuations in the binding constants with chain length revealed regions in the binding site with polar characteristics. Binding constants to an intermediate form of the enzyme (intermediate II) were also determined, and these confirmed the principal features of the binding site deduced from the peak height measurements. The long-chain compounds, however, bound considerably tighter to the intermediate II form of the enzyme, and this was shown to account for the biphasic decay kinetics that were observed with these compounds. Overall, there was poor agreement between the EC50 concentrations for inhibiting the luciferase enzyme from V. harveyi and those which induce general anesthesia in animals, with bulky compounds being much less potent, and moderately long chain alcohols being much more potent, as luciferase inhibitors than as general anesthetics.
研究了36种不同的全身麻醉剂和类麻醉化合物对哈维氏弧菌高度纯化的细菌荧光素酶制剂的影响。在黄素位点饱和的条件下,几乎所有的麻醉剂都抑制了酶的峰值活性并减缓了衰减速率。然而,少数极性较强的试剂仅在高浓度时才产生抑制作用,而在低浓度时则刺激活性。结果发现这种抑制本质上是竞争性的,麻醉剂通过竞争醛底物正癸醛的结合起作用。酶上的麻醉剂结合位点只能容纳一个大分子麻醉剂分子,但能容纳多个小分子麻醉剂分子,这与该位点具有特定尺寸相符。正构醇和正构烷烃的同系物在抑制效力上表现出截止值,但这些截止值出现在非常不同的链长(正构烷烃约为C10,正构醇约为C15),这与在动物中观察到的全身麻醉效力的类似截止值相似。通过峰值高度测量确定的结合常数表明,抑制剂结合位点主要是疏水的(平均每CH2的ΔΔG为 -5.0 kJ/mol),但结合常数随链长的波动揭示了结合位点中具有极性特征的区域。还测定了与酶的中间形式(中间体II)的结合常数,这些常数证实了从峰值高度测量推断出的结合位点的主要特征。然而,长链化合物与酶的中间体II形式结合得更紧密,这被证明可以解释用这些化合物观察到的双相衰减动力学。总体而言,抑制哈维氏弧菌荧光素酶的EC50浓度与在动物中诱导全身麻醉的浓度之间的一致性较差,体积较大的化合物作为荧光素酶抑制剂的效力远低于作为全身麻醉剂,而中等长度链的醇类作为荧光素酶抑制剂的效力比作为全身麻醉剂要强得多。